V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Conmed Executive Compensation (FY25)

CNMD · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Patrick Beyer
Latest say-on-pay support
=
May 18, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Conmed brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 18, 2026Latest filing (8-K): May 20, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Conmed brief$1,500Get the executive brief
Velarion Member, one year
350 figures on this page: 340 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Patrick Beyer: $4,300,085 → $7,634,873 (77.6% higher)
Say-on-pay support: 96.9% → 93.8% (3.1 points lower)
CEO pay ratio: 177:1 → 152:1 (14.1% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Conmed's chief executive and what were they paid?
Patrick Beyer was paid $7,634,873 in total compensation as President and Chief Executive Officer for fiscal 2025. Beyer's total was 77.6% higher than the $4,300,085 reported for fiscal 2024.
What was Conmed's say-on-pay result?
Shareholders supported the say-on-pay proposal with 93.8% of votes cast for or against in favor at the meeting held May 18, 2026 for fiscal 2025.
Which companies are in Conmed's peer group?
Companies named in the disclosed peer group include AtriCure, Inc., Avanos Medical, Inc., Enovis Corporation, Globus Medical, Inc. and Haemonetics Corporation, among others.
What is Conmed's chief executive pay ratio?
The company reported a chief executive pay ratio of 152:1 for fiscal 2025, against median employee compensation of $50,348.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Curt Hartman
Chair of the Board, President & Chief Executive Officer
◇——◇◇—◇◇
Patrick Beyer
President, CONMED International & Global Orthopedics 7
◇◇—◇◇—◇◇
Todd Garner
Executive Vice President and Chief Financial Officer
◇◇—◇◇—◇◇
Stanley Peters
Vice President & General Manager, U.S. Advanced Surgical
◇◇—◇◇—◇◇
Heather Cohen
Executive Vice President & Chief Human Resources and Legal Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Curt Hartman
Chair, President & Chief Executive Officer
◇—◇◇◇—◇◇
Patrick Beyer
President, International & Global Orthopedics
◇—◇◇◇—◇◇
Todd Garner
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Stanley Peters
President, Advanced Surgical & Advanced Endoscopic Technologies
◇—◇◇◇—◇◇
Heather Cohen
Executive Vice President & Chief Human Resources and Legal Officer & Secretary
◇—◇◇◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Curt Hartman
Chair, President & Chief Executive Officer
◇—◇◇◇—◇◇
Todd Garner
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Patrick Beyer
Chief Operating Officer
◇—◇◇◇—◇◇
Stanley Peters
President, Advanced Surgical & Advanced Endoscopic Technologies
◇—◇◇——◇◇
Heather Cohen
Executive Vice President & Chief Human Resources and Legal Officer & Secretary
◇—◇◇◇—◇◇
Peter Shagory
EVP Strategy & Corp Development
◇—◇◇◇—◇◇
Brent Lalomia
Vice President, Quality Assurance, Regulatory Affairs, Customer Experience, and Logistics
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Patrick Beyer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Todd Garner
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Hollie Foust
Executive Vice President, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Brent Lalomia
Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations
◇◇◇◇◇—◇◇
Peter Shagory
Executive Vice President, Strategy and Corporate Development
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brent LalomiaPSU◇◇◇—◇—◇
Brent LalomiaOPTION◇——◇—◇◇
Hollie FoustPSU◇◇◇—◇—◇
Hollie FoustOPTION◇——◇—◇◇
Patrick J. BeyerOPTION◇——◇—◇◇
Patrick J. BeyerPSU◇◇◇—◇—◇
Peter K. ShagoryOPTION◇——◇—◇◇
Peter K. ShagoryPSU◇◇◇—◇—◇
Todd W. GarnerPSU◇◇◇—◇—◇
Todd W. GarnerOPTION◇——◇—◇◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Peter ShagoryRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
Option◇—◇3/1/2027
Option◇—◇3/1/2034
Option◇—◇3/1/2029
Option◇—◇3/1/2028
Option◇—◇3/1/2033
Option◇—◇3/2/2030
Option◇—◇3/3/2035
Option◇—◇3/1/2031
Todd GarnerRSU◇◇——
Option◇—◇3/1/2031
Option◇—◇3/1/2033
Option◇—◇3/1/2034
Option◇—◇3/3/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
Brent LalomiaRSU◇◇——
Option◇—◇3/1/2033
Option◇—◇6/17/2029
Option◇—◇3/3/2035
Option◇—◇3/1/2032
Option◇—◇3/1/2034
Option◇—◇3/1/2031
Option◇—◇3/2/2030
RSU◇◇——
RSU◇◇——
Patrick BeyerRSU◇◇——
Option◇—◇3/1/2034
Option◇—◇3/1/2033
Option◇—◇3/1/2032
Option◇—◇4/24/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2031
Option◇—◇1/2/2035
Hollie FoustOption◇—◇3/3/2035
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Kaye
◇◇◇———◇
LaVerne H. Council
Board chair
◇◇◇———◇
Barbara J. Schwarzentraub
◇◇◇———◇
David Bronson
◇◇◇———◇
Brian P. Concannon
◇◇◇———◇
Charles M. Farkas
◇◇◇———◇
Martha Goldberg Aronson
◇◇◇———◇
Kim Kelderman
◇◇◇———◇
Dr. John L. Workman
◇—————◇
Patrick J. Beyer served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Stock Options (80%) and RSUs (20%).
Stock ownership guideline: 5x annual Board retainer fee

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AtriCure, Inc. ATRC
  • Avanos Medical, Inc. AVNS
  • Enovis Corporation ENOV
  • Globus Medical, Inc. GMED
  • Haemonetics Corporation HAE
  • ICU Medical, Inc. ICUI
  • Integra LifeSciences Holdings Corporation IART
  • LivaNova PLC LIVN
  • Masimo Corporation MASI
  • Merit Medical Systems, Inc. MMSI
  • Penumbra, Inc. PEN
  • Teleflex Incorporated TFX
  • Varex Imaging Corporation VREX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 18, 2026=◇◇◇
2024May 20, 2025=◇◇◇
2023May 22, 2024=◇◇◇
2022May 24, 2023=◇◇◇
2021May 25, 2022=◇◇◇
2020May 19, 2021=◇◇◇
2018May 22, 2019=◇◇◇
2017May 23, 2018=◇◇◇
2016May 24, 2017=◇◇◇
2015May 25, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Patrick Beyer (President and Chief Executive Officer), FY2025 total compensation $7,634,873 (base salary $891,100) [exec_comp, SEC accession 0000816956-26-000047, filed 2026-04-07]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Conmed files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Conmed disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Conmed sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Conmed's disclosed peer group is defensible, who names Conmed back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
350 figures on this page: 340 cited to the filing that reported them, 10 calculated from figures it prints.
340 cited to the filing
10 calculated from the filing

Documents cited

  1. 0000816956-26-000057
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000816956-26-000047
    2025 Non-Employee Director Compensation Table · Director Compensation · Grants of Plan-Based Awards · Grants of Plan-Based Awards Table in 2025 · and 2 more sections
  3. 0001174947-25-000828
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-25-075693
    Summary Compensation Table
  5. 0001104659-24-064334
  6. 0001193125-24-089093
    Summary Compensation Table
  7. 0001193125-23-152961
  8. 0001193125-23-097090
    SUMMARY COMPENSATION TABLE
  9. 0001193125-22-159963
  10. 0001193125-21-167763
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001174947-19-000723
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001174947-18-000866
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001174947-17-000927
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001174947-16-002738
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Conmed executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CNMD (accessed 2026).
Short form: data: Velarion

The Conmed brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Conmed and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Conmed discloses

The companies named in CNMD's own disclosed peer group.

AtriCure, Inc.Avanos Medical, Inc.Enovis CorporationGlobus Medical, Inc.Haemonetics CorporationICU Medical, Inc.Integra LifeSciences Holdings CorporationLivaNova PLCMasimo CorporationMerit Medical Systems, Inc.Penumbra, Inc.Teleflex IncorporatedVarex Imaging Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy